Clinical utility of antifungal susceptibility testing

Todd P McCarty; Paul M Luethy; John W Baddley; Peter G Pappas

doi:10.1093/jacamr/dlac067

Clinical utility of antifungal susceptibility testing

JAC Antimicrob Resist. 2022 Jun 28;4(3):dlac067. doi: 10.1093/jacamr/dlac067. eCollection 2022 Jun.

Authors

Todd P McCarty¹, Paul M Luethy², John W Baddley³, Peter G Pappas¹

Affiliations

¹ Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
² Department of Pathology, University of Maryland, Baltimore, MD, USA.
³ Department of Medicine, University of Maryland, Baltimore, MD, USA.

Abstract

Invasive fungal diseases cause significant morbidity and mortality, in particular affecting immunocompromised patients. Resistant organisms are of increasing importance, yet there are many notable differences in the ability to both perform and interpret antifungal susceptibility testing compared with bacteria. In this review, we will highlight the strengths and limitations of resistance data of pathogenic yeasts and moulds that may be used to guide treatment and predict clinical outcomes.

Publication types

Review